» Articles » PMID: 35739227

Construction of a Four-mRNA Prognostic Signature with Its CeRNA Network in CESC

Overview
Journal Sci Rep
Specialty Science
Date 2022 Jun 23
PMID 35739227
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) tumorigenesis involves a combination of multiple genetic alteration processes. Constructing a survival-associated competing endogenous RNA (ceRNA) network and a multi-mRNA-based prognostic signature model can help us better understand the complexity and genetic characteristics of CESC. In this study, the RNA-seq data and clinical information of CESC patients were downloaded from The Cancer Genome Atlas. Differentially expressed mRNAs, lncRNAs and miRNAs were identified with the edgeR R package. A four-mRNA prognostic signature was developed by multivariate Cox regression analysis. Kaplan-Meier survival with the log-rank tests was performed to assess survival rates. The relationships between overall survival (OS) and clinical parameters were evaluated by Cox regression analysis. A survival-associated ceRNA network was constructed with the multiMiR package and miRcode database. Kyoto encyclopedia of genes and genomes (KEGG) analysis and gene ontology analyses were used to identify the functional role of the ceRNA network in the prognosis of CESC. A total of 298 differentially expressed mRNAs, 8 miRNAs, and 29 lncRNAs were significantly associated with the prognosis of CESC. A prognostic signature model based on 4 mRNAs (OPN3, DAAM2, HENMT1, and CAVIN3) was developed, and the prognostic ability of this signature was indicated by the AUC of 0.726. Patients in the high-risk group exhibited significantly worse OS. The KEGG pathways, TGF-β and Cell adhesion molecules, were significantly enriched. In this study, a CESC-associated ceRNA network was constructed, and a multi-mRNA-based prognostic model for CESC was developed based on the ceRNA network, providing a new perspective for cancer pathogenesis research.

Citing Articles

CENPE is a diagnostic and prognostic biomarker for cervical cancer.

Peng P, Zheng J, He K, Wang K, Wang L, Zheng X Heliyon. 2025; 10(24):e40860.

PMID: 39759304 PMC: 11698922. DOI: 10.1016/j.heliyon.2024.e40860.


Identification and Validation of eRNA as a Prognostic Indicator for Cervical Cancer.

Huang L, Zhang J, Songyang Z, Xiong Y Biology (Basel). 2024; 13(4).

PMID: 38666838 PMC: 11048606. DOI: 10.3390/biology13040227.


Unraveling the role of the circadian clock genes in cervical squamous cell carcinoma and endocervical adenocarcinoma: A prognostic indicator for prognostic, immunotherapy response, and chemotherapy sensitivity.

Xu J, Huang X, Gou S, Luo H, Zeng S, Zhang Q J Cancer. 2024; 15(9):2788-2804.

PMID: 38577592 PMC: 10988312. DOI: 10.7150/jca.94063.


The miR-146b-3p/TNFAIP2 axis regulates cell differentiation in acute myeloid leukaemia.

Lan G, Wu X, Zhao A, Lan J, Guo Q, Wang B Aging (Albany NY). 2024; 16(2):1496-1515.

PMID: 38271140 PMC: 10866442. DOI: 10.18632/aging.205441.


Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.

Zhou J, Xu L, Zhou H, Wang J, Xing X Genes (Basel). 2023; 14(7).

PMID: 37510286 PMC: 10379127. DOI: 10.3390/genes14071381.


References
1.
Bavelloni A, Ramazzotti G, Poli A, Piazzi M, Focaccia E, Blalock W . MiRNA-210: A Current Overview. Anticancer Res. 2017; 37(12):6511-6521. DOI: 10.21873/anticanres.12107. View

2.
Deng M, Cai X, Long L, Xie L, Ma H, Zhou Y . CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-β. J Transl Med. 2019; 17(1):352. PMC: 6815430. DOI: 10.1186/s12967-019-2098-6. View

3.
An X, Lin X, Yang A, Jiang Q, Geng B, Huang M . Cavin3 Suppresses Breast Cancer Metastasis Inhibiting AKT Pathway. Front Pharmacol. 2020; 11:01228. PMC: 7556234. DOI: 10.3389/fphar.2020.01228. View

4.
Feng B, Wang R, Chen L . Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother. 2012; 66(6):397-402. DOI: 10.1016/j.biopha.2012.06.002. View

5.
Teng Y, Su X, Zhang X, Zhang Y, Li C, Niu W . miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. Oncotarget. 2016; 7(49):81621-81633. PMC: 5348417. DOI: 10.18632/oncotarget.13154. View